Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose Escalation and Dose-Expansion Study (vol 35, pg 157, 2017)

被引：0
|
作者：
Burris, Howard A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358 / 358
页数：1
相关论文
共 50 条
  • [21] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 7, pg 704, 2017)
    Baselga, Jose
    CANCER DISCOVERY, 2018, 8 (11) : 1491 - 1491
  • [22] A phase I/IIa dose escalation study of AFM24 in patients with epidermal growth factor receptor-expressing (EGFR) solid tumors: Results from phase I
    El-Khoueiry, A. B.
    Lopez, J. S.
    Saavedra, O.
    Awad, M.
    Thomas, J.
    Tiu, C.
    Garralda, E.
    Rehbein, B.
    Hintzen, G.
    Pietzko, K.
    Raab, C.
    Rajkovic, E.
    Ravenstijn, P.
    Rivas, D.
    Emig, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S889 - S889
  • [23] A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma
    Li, W.
    Kang, Z.
    Wu, Z.
    Li, S.
    Huang, M.
    Pu, W.
    Yang, X.
    Lin, J.
    Liu, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S394 - S395
  • [24] Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Tolcher, Anthony W.
    Patnaik, Amita
    Rasco, Drew Warren
    Chambers, Glenda
    Beeram, Murali
    Savage, Ronald
    Hall, Terence
    Schwartz, Brian E.
    Kazakin, Julia
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
    Noboru Yamamoto
    Baek-Yeol Ryoo
    Bhumsuk Keam
    Masatoshi Kudo
    Chia-Chi Lin
    Futoshi Kunieda
    Howard A. Ball
    Diarmuid Moran
    Kanji Komatsu
    Kentaro Takeda
    Musashi Fukuda
    Junji Furuse
    Satoshi Morita
    Toshihiko Doi
    Investigational New Drugs, 2020, 38 : 445 - 456
  • [26] A phase I dose escalation study of BIBW 2992, an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR-1) and 2 (HER 2) in a 2 week on 2 week off schedule in patients with advanced solid tumors.
    Eskens, FA
    Mom, CH
    Planting, AS
    Gietema, JA
    Aamelsberg, A
    Huisman, H
    Verweij, J
    de Vries, EG
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9023S - 9023S
  • [27] An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.
    Eskens, F. A.
    Planting, A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 87S - 87S
  • [28] A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies
    Yamamoto, Noboru
    Ryoo, Baek-Yeol
    Keam, Bhumsuk
    Kudo, Masatoshi
    Lin, Chia-Chi
    Kunieda, Futoshi
    Ball, Howard A.
    Moran, Diarmuid
    Komatsu, Kanji
    Takeda, Kentaro
    Fukuda, Musashi
    Furuse, Junji
    Morita, Satoshi
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 445 - 456
  • [29] Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors
    Noboru Yamamoto
    Atsushi Horiike
    Yasuhito Fujisaka
    Haruyasu Murakami
    Tatsu Shimoyama
    Yasuhide Yamada
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 489 - 496
  • [30] Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.
    Evana, T.
    Lindsay, C. R.
    Chan, E.
    Tait, B.
    Michael, S. A.
    Day, S.
    Stephens, A. W.
    Franke, A.
    Poondru, S.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345